Shares of healthcare tech company GoodRx (NASDAQ:GDRX) jumped 40.2% in the afternoon session after the company announced a ...

GoodRx will offer the GLP-1s for $499 a month, the lowest-ever out-of-pocket cost for the weight-loss medications.

GoodRx shares are pulling back Tuesday morning. The stock had jumped over 30% Monday after the company announced a new ...

We recently published 12 Best Healthcare Stocks to Buy Under $30. GoodRx Holdings, Inc. (NASDAQ:GDRX) is one of the best ...

GoodRx Holdings, Inc.'s partnership with Novo Nordisk highlights its vital role in direct-to-consumer drug pricing. Click ...

Interestingly, Wall Street firms largely believe the former will playout in the long run. According to The Wall Street ...

GoodRx (Nasdaq: GDRX) has teamed up with Novo Nordisk (NOV: N) to make all dose levels of Ozempic (semaglutide) and Wegovy ...

Health Canada approved Ozempic for type 2 diabetes patients with chronic kidney disease after positive FLOW trial results.

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

GoodRx is joining the GLP-1 action with an announcement Monday to begin selling both Novo Nordisk's GLP-1 drugs, Ozempic and Wegovy, at a cash price of $499 per month.

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

GoodRx Holdings Inc (NASDAQ:GDRX) is set to release its Q2 2025 earnings on Aug 6, 2025. The consensus estimate for Q2 2025 ...